SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with oestrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA-mutant tumours

被引：2
|
作者：
Baselga, J. [1 ]
Cortes Castan, J. [2 ,3 ]
De Laurentiis, M. [4 ]
Dieras, V. [5 ]
Harbeck, N. [6 ]
Hsu, J. [7 ]
Jin, H. [8 ]
Schimmoller, F.
Wilson, T. R. [9 ]
Im, Y-H. [10 ]
Jacot, W. [11 ]
Krop, I. E. [12 ]
Verma, S. [13 ]
机构：
[1] Mem Hosp, Mem Sloan Kettering Canc Ctr, Dept Med, Human Oncol & Pathogenesis Program HOPP, New York, NY USA
[2] Vall dHebron Inst Oncol VHIO, Dept Med Oncol, Barcelona, Spain
[3] Ramon & Cajal Univ Hosp, Madrid, Spain
[4] Fdn G Pascale, Ist Nazl Tumori, Breast Oncol Dept, Naples, Italy
[5] Inst Curie, Dept Med Oncol, Paris, France
[6] Univ Munich, Breast Canc Ctr, Munich, Germany
[7] Genentech Inc, Prod Dev Oncol, San Francisco, CA 94080 USA
[8] Genentech Inc, Dept Oncol, San Francisco, CA 94080 USA
[9] Genentech Inc, Oncol Biomarker Dept, San Francisco, CA 94080 USA
[10] Samsung Med Ctr, Dept Med, Seoul, South Korea
[11] Inst Canc Montpellier ICM, Dept Med Oncol, Montpellier, France
[12] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[13] Univ Calgary, Dept Oncol, Tom Baker Canc Ctr, Calgary, AB, Canada
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw365.92
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
313TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Circulating tumor DNA (ctDNA) analysis of PIK3CA and AKT1 mutations in patients enrolled onto the Phase 1b study of the PI3K inhibitor taselisib (GDC-0032) in solid malignancies
    Wilson, Timothy R.
    Savage, Heidi
    Aimi, Junko
    Jin, Jessica
    Parmar, Hema
    Hsu, Jerry
    Krop, Ian
    Saura, Cristina
    Cervantes, Andres
    Sachdev, Jasgit
    Patel, Manish
    Cejalvo, Juan
    Oliveira, Mafalda
    Winer, Eric
    Von Hoff, Daniel
    Baselga, Jose
    Juric, Dejan
    CANCER RESEARCH, 2015, 75
  • [32] INAVO121: Phase III study of inavolisib plus fulvestrant vs alpelisib plus fulvestrant in patients with hormone receptorpositive, HER2-negative, PIK3CAmutated locally advanced or metastatic breast cancer
    Juric, Dejan
    Kalinsky, Kevin
    Im, Seock-Ah
    Ciruelos, Eva
    Bianchini, Giampaolo
    Barrios, Carlos
    Jacot, William
    Schmid, Peter
    Loi, Sherene
    Rugo, Hope
    Craine, Veronica
    Hutchinson, Katherine
    Flechais, Aulde
    Thanopoulou, Eirini
    Harbeck, Nadia
    CANCER RESEARCH, 2024, 84 (09)
  • [33] Phase Ia/Ib study of taselisib (GDC-0032), a potent and selective phosphoinositide 3-kinase inhibitor, in Japanese patients with advanced solid tumors or hormone receptor-positive locally advanced or metastatic breast cancer (JO29196 study)
    Kobayashi, T.
    Nakano, K.
    Tomomatsu, J.
    Nara, E.
    Ito, Y.
    Kobayashi, K.
    Fukada, I.
    Araki, K.
    Shimomura, A.
    Shimoi, T.
    Kodaira, M.
    Yunokawa, M.
    Yonemori, K.
    Shimizu, C.
    Nakamura, K.
    Kotani, N.
    Inatani, M.
    Tamura, K.
    Takahashi, S.
    CANCER RESEARCH, 2016, 76
  • [34] Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study
    Vuylsteke, P.
    Huizing, M.
    Petrakova, K.
    Roylance, R.
    Laing, R.
    Chan, S.
    Abell, F.
    Gendreau, S.
    Rooney, I.
    Apt, D.
    Zhou, J.
    Singel, S.
    Fehrenbacher, L.
    ANNALS OF ONCOLOGY, 2016, 27 (11) : 2059 - 2066
  • [35] Results of the phase Ib dose escalation study of MEN1611, a PI3K inhibitor, combined with trastuzumab (T) ± fulvestrant (F) for HER2+/PIK3CA mutant (mut) advanced or metastatic (a/m) breast cancer (BC)
    Piccart, M.
    Ruiz Borrego, M.
    Duhoux, F.
    Arkenau, H-T.
    Doger de Speville, B.
    Wildiers, H.
    Campone, M.
    Tosi, D.
    Garcia-Corbacho, J.
    Jimenez, B.
    Escriva-de Romani, S.
    Wardley, A. M.
    Tassone, P.
    Boni, V.
    Jerez, Y.
    Aftimos, P. G.
    Hennequin, A.
    Amair-Pinedo, F.
    Pellacani, A. U. E.
    Laurent, D. O.
    ANNALS OF ONCOLOGY, 2020, 31 : S386 - S386
  • [36] Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells
    Fujimoto, Yumi
    Morita, Tomoko Yamamori
    Ohashi, Akihiro
    Haeno, Hiroshi
    Hakozaki, Yumi
    Fujii, Masanori
    Kashima, Yukie
    Kobayashi, Susumu S.
    Mukohara, Toru
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [37] Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells
    Yumi Fujimoto
    Tomoko Yamamori Morita
    Akihiro Ohashi
    Hiroshi Haeno
    Yumi Hakozaki
    Masanori Fujii
    Yukie Kashima
    Susumu S. Kobayashi
    Toru Mukohara
    Scientific Reports, 10
  • [38] The FERGI phase II study of the PI3K inhibitor pictilisib (GDC-0941) plus fulvestrant vs fulvestrant plus placebo in patients with ER plus , aromatase inhibitor ( AI) resistant advanced or metastatic breast cancer - Part I results
    Krop, Ian
    Johnston, Stephen
    Mayer, Ingrid A.
    Dickler, Maura
    Ganju, Vinod
    Forero-Torres, Andres
    Melichar, Bohuslav
    Morales, Serafin
    de Boer, Richard
    Gendreau, Steven
    Derynck, Mika
    Lackner, Mark
    Spoerke, Jill
    Yeh, Ru-Fang
    Levy, Gallia
    Ng, Vivian
    O'Brien, Carol
    Savage, Heidi
    Xiao, Yuanyuan
    Wilson, Timothy
    Lee, Soo Chin
    Petrakova, Katarina
    Vallentin, Susanne
    Yardley, Denise
    Ellis, Matthew
    Piccart, Martine
    Perez, Edith A.
    Winer, Eric
    Schmid, Peter
    CANCER RESEARCH, 2015, 75
  • [39] Phase I study of PI3Kα inhibitor BYL719+aromatase inhibitor (AI) in patients (pts) with hormone receptor-positive (HR plus ) metastatic breast cancer (MBC)
    Shah, Payal D.
    Moynahan, Mary E.
    Modi, Shanu
    Hamilton, Nicola
    Caravella, Betty Ann
    Zamora, Stephen
    Dang, Chau
    Gilewski, Theresa
    Traina, Tiffany
    Comen, Elizabeth
    Sugarman, Steven M.
    D'Andrea, Gabriella
    Lake, Diana
    Goldfarb, Shari
    Patil, Sujata
    Covey, Anne
    Berger, Michael
    Lacouture, Mario
    Norton, Larry
    Hudis, Clifford A.
    BaseIga, Jose
    Chandarlapaty, Sarat
    Dickler, Maura
    CANCER RESEARCH, 2015, 75
  • [40] FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer
    Narayan, Preeti
    Prowell, Tatiana M.
    Gao, Jennifer J.
    Fernandes, Laura L.
    Li, Emily
    Jiang, Xiling
    Qiu, Junshan
    Fan, Jianghong
    Song, Pengfei
    Yu, Jingyu
    Zhang, Xinyuan
    King-Kallimanis, Bellinda L.
    Chen, Wei
    Ricks, Tiffany K.
    Gong, Yutao
    Wang, Xing
    Windsor, Katherine
    Rhieu, Steve Y.
    Geiser, Gerlie
    Banerjee, Anamitro
    Chen, Xiaohong
    Turcu, Francisca Reyes
    Chatterjee, Deb K.
    Pathak, Anand
    Seidman, Jeffrey
    Ghosh, Soma
    Philip, Reena
    Goldberg, Kirsten B.
    Kluetz, Paul G.
    Tang, Shenghui
    Amiri-Kordestani, Laleh
    Theoret, Marc R.
    Pazdur, Richard
    Beaver, Julia A.
    CLINICAL CANCER RESEARCH, 2021, 27 (07) : 1842 - 1849
12345